Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC vaccine and CIK cells in AML
NCT01898663Phase 2Recruiting
- Sponsor
- Academy of Military Medical Sciences
- Start
- Jun 2013
- Primary completion
- Dec 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of unmodified CIK in acute myeloid leukemia (AML), sponsored by Academy of Military Medical Sciences. Started Jun 2013; status: recruiting.
02
Drugs
unmodified CIK
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01898663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01898663.